Terminated PHASE2 INTERVENTIONAL 1-arm NCT01914718

Dose-adjusted EPOCH-R in MYC Positive DLBCL

Dose-adjusted EPOCH-R in Patients With Diffuse Large B-cell Lymphoma: a Phase II Study

Sponsor: Fudan University

Conditions Diffuse Large B-cell Lymphoma

Interventions DA-EPOCH-R

Updated 5 times since 2017 Last updated: Aug 19, 2014 Started: Feb 28, 2013 Primary completion: Dec 31, 2015 Completion: Dec 31, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Poor accrual of eligible patients

Other terminated trials from Fudan University

See all terminations from Fudan University

Other Diffuse Large B-cell Lymphoma trials with similar outcome

Browse all Diffuse Large B-cell Lymphoma trials

A PHASE2 clinical study on Diffuse Large B-cell Lymphoma, this trial is terminated or withdrawn. The trial is conducted by Fudan University and has accumulated 5 data snapshots since 2013. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE2
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2
Jan 2017 — Jun 2018 [monthly]

Terminated PHASE2

First recorded

Feb 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Fudan University

Data source: Fudan University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China